Vanguard Group
MIRM icon

Vanguard Group’s Mirum Pharmaceuticals MIRM Stock Holding History

Vanguard Group’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$205M Buy
2,596,089
+50,720
+2% +$3.64M ﹤0.01% 1539
2025
Q3 		$187M Sell
2,545,369
-19,500
-0.8% -$1.24M ﹤0.01% 1572
2025
Q2 		$131M Buy
2,564,869
+24,808
+1% +$1.1M ﹤0.01% 1714
2025
Q1 		$114M Buy
2,540,061
+115,327
+5% +$5.44M ﹤0.01% 1739
2024
Q4 		$100M Sell
2,424,734
-71,378
-3% -$2.97M ﹤0.01% 1869
2024
Q3 		$97.3M Buy
2,496,112
+49,379
+2% +$1.97M ﹤0.01% 1882
2024
Q2 		$83.7M Buy
2,446,733
+235,048
+11% +$6.16M ﹤0.01% 1920
2024
Q1 		$55.6M Sell
2,211,685
-264,559
-11% -$7.27M ﹤0.01% 2123
2023
Q4 		$73.1M Buy
2,476,244
+782,901
+46% +$23.7M ﹤0.01% 2013
2023
Q3 		$53.5M Buy
1,693,343
+98,685
+6% +$2.7M ﹤0.01% 2101
2023
Q2 		$41.3M Buy
1,594,658
+320,831
+25% +$8.53M ﹤0.01% 2272
2023
Q1 		$30.6M Buy
1,273,827
+11,529
+0.9% +$263K ﹤0.01% 2405
2022
Q4 		$24.6M Buy
1,262,298
+17,373
+1% +$343K ﹤0.01% 2527
2022
Q3 		$26.2M Buy
1,244,925
+261,950
+27% +$6.31M ﹤0.01% 2516
2022
Q2 		$19.1M Buy
982,975
+217,791
+28% +$5.14M ﹤0.01% 2657
2022
Q1 		$16.9M Sell
765,184
-43,165
-5% -$881K ﹤0.01% 2871
2021
Q4 		$12.9M Buy
808,349
+73,702
+10% +$1.15M ﹤0.01% 3085
2021
Q3 		$14.6M Buy
734,647
+3,150
+0.4% +$51.2K ﹤0.01% 3033
2021
Q2 		$12.6M Sell
731,497
-9,377
-1% -$168K ﹤0.01% 3090
2021
Q1 		$14.7M Buy
740,874
+113,078
+18% +$2.16M ﹤0.01% 2942
2020
Q4 		$11M Buy
627,796
+147,712
+31% +$2.9M ﹤0.01% 2945
2020
Q3 		$9.25M Buy
480,084
+7,067
+1% +$152K ﹤0.01% 2827
2020
Q2 		$9.21M Buy
473,017
+299,240
+172% +$5M ﹤0.01% 2813
2020
Q1 		$2.43M Buy
173,777
+93,344
+116% +$1.53M ﹤0.01% 3248
2019
Q4 		$1.97M Sell
80,433
-1,423
-2% -$15.2K ﹤0.01% 3459
2019
Q3 		$823K Buy
+81,856
New +$1M ﹤0.01% 3698

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group's MIRM Position: Q4 2025 in Review

Vanguard Group increased its Mirum Pharmaceuticals (MIRM) stake by 2% in Q4 2025, buying an estimated $3.64M and bringing the position to 2,596,089 shares worth $205M. The position accounts for ﹤0.01% of the portfolio, ranked #1539.

Vanguard Group first reported a position in MIRM in Q3 2019 and has held it in 26 quarters since. 281 funds tracked by Wall St. Rank hold MIRM as of Q4 2025.

  • Vanguard Group held 2,596,089 shares of Mirum Pharmaceuticals worth $205M as of Q4 2025.
  • Vanguard Group bought 50,720 Mirum Pharmaceuticals shares in Q4 2025, an estimated $3.64M.
  • Mirum Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1539 holding.
  • Vanguard Group first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 26 quarters since.
  • 281 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.